New targeted drug shows promise for rare cancer mutation

NCT ID NCT06533059

Ongoing Disease control Sponsor: Alterome Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This early-stage trial tests a new drug, ALTA2618, in about 110 adults whose advanced solid tumors (like breast or endometrial cancer) have a specific genetic change called AKT1 E17K. The main goals are to check the drug's safety and find the right dose. Participants must have tried other treatments first or not been able to take them.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cancer endometrial cancer endometrium neoplasm female reproductive system neoplasm metastatic malignant neoplasm neoplasm Neoplasm Metastasis ovarian cancer prostate cancer triple-negative breast carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR BREAST CANCER CANCER ENDOMETRIAL CANCER METASTATIC CANCER

Contacts and locations

Locations

Research Site

La Jolla, California, 92093, United States
Research Site

Denver, Colorado, 80218, United States
Research Site

Sarasota, Florida, 34232, United States
Research Site

Boston, Massachusetts, 02114, United States
Research Site

Boston, Massachusetts, 02215, United States
Research Site

St Louis, Missouri, 63110, United States
Research Site

Nashville, Tennessee, 37203, United States
Research Site

Houston, Texas, 77030, United States
Research Site

San Antonio, Texas, 78229, United States
Research Site

Fairfax, Virginia, 22031, United States
Research Site

Madison, Wisconsin, 53792, United States
Research Site

Randwick, New South Wales, 2031, Australia
Research Site

Malvern, Victoria, 3144, Australia
Research Site

Nedlands, Western Australia, 6009, Australia
Research Site

Caen, 14000, France
Research Site

Villejuif, 94800, France
Research Site

Kyoto, 606-8507, Japan
Research Site

Tokyo, 135-8550, Japan
Research Site

Seoul, 06591, South Korea
Research Site

Seoul, 13620, South Korea
Research Site

Barcelona, 08035, Spain
Research Site

Barcelona, 08908, Spain
Research Site

Madrid, 28023, Spain
Research Site

Madrid, 28040, Spain
Research Site

Taipei, 100, Taiwan
Research Site

London, SW3 6JJ, United Kingdom
Research Site

London, W1G 6AD, United Kingdom
Research Site

Manchester, M10 4BX, United Kingdom
Research Site

Newcastle upon Tyne, NE7 7DN, United Kingdom
Research Site

Sutton, SM2 5PT, United Kingdom
Research Site #2

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.